New lupus drug cizutamig enters early human safety trials
NCT ID NCT07215663
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study is testing a new drug called cizutamig in about 47 adults with systemic lupus erythematosus (SLE), a chronic autoimmune disease. The main goal is to check if the drug is safe and tolerable, and to see how it moves through the body. Participants must have active lupus that hasn't responded well enough to prior treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese Academy of Medical Sciences and Peking Union Medical College Hospital
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Three-Drug combo quiet lupus kidney flares?
- Can a new antibody tame lupus flares?
- Can a single infusion of reprogrammed immune cells quiet lupus kidney disease?
- Eye tests could spot silent vision damage in lupus patients
- Could a simple blood test predict lupus in children with ITP?
- Can an extra shot boost COVID protection in autoimmune patients?